Zymeworks Inc. announced in connection with the Restructuring, effective January 19, 2022, the Company terminated the employment of Dr. Anthony Polverino, Executive Vice President, Early Development & Chief Scientific Officer and in connection with the Restructuring, effective January 19, 2022, the Company terminated the employment of Ms. Kathryn O'Driscoll, Chief People Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.07 USD | +2.03% |
|
+13.40% | -3.08% |
Jun. 17 | Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy | MT |
Jun. 17 | Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.08% | 703M | |
+20.12% | 127B | |
+25.25% | 117B | |
+25.56% | 27.77B | |
-19.51% | 20.44B | |
-14.36% | 16.62B | |
-15.63% | 15.92B | |
-46.67% | 14.94B | |
+11.89% | 14.74B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc. Announces Management Changes